US Pharma MarketingAccurKardia has been granted a U.S. patent for a machine learning-based system designed to identify cardiac amyloidosis from a standard 12-lead electrocardiogram, positioning the ECG analytics company to expand its investigational AI-ECG pipeline into a disease area where diagnosis is often delayed.
AccurKardia receives patent for AI-ECG cardiac amyloidosis detection
The company says its machine learning approach could help flag cardiac amyloidosis from standard 12-lead ECGs, though experts say real-world validation and accuracy will be key. AccurKardia has been granted a U.S. patent for a machine learning-based system designed to identify cardiac amyloidosis from a standard 12-lead electrocardiogram, positioning the ECG analytics company to expand its investigational AI-ECG pipeline into a disease area where diagnosis is often delayed. The company announced that it received U.S. Patent No. 12,620,488 for its proprietary system, which aims to use routinely performed ECG data to detect cardiac amyloidosis, a serious heart disease in which…
Source: MobiHealthNews